ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Sloan-Kettering Sues Empire Blue Cross Over Reimbursement

September 17, 1993

GM Cancer Research Foundation Awards $750,000 To Five Scientists For Their Work

June 8, 2001

IVAX Agreement With Rival BMS Appears To Buttress BMS control of Paclitaxel

November 26, 1999

ACS Funds $54 Million in Grants

June 28, 2002

FDA Lacks Resources To Deal With Onslaught Of New Cancer Drugs, Friedman Tells Agency

August 14, 1992

Paul Okunieff Named Director At UF Shands Cancer Center

October 16, 2009